ArticleFrontiers in public health2026
Public awareness, attitudes, and concerns regarding pharmacogenomics in the Kingdom of Saudi Arabia: an exploratory online cross-sectional survey.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacogenomics (PGx) is a cornerstone of precision medicine, enabling tailored drug therapy based on an individual's genetic profile. However, public awareness, attitudes, and concerns regarding PGx testing in Saudi Arabia remain largely unexplored. This study aimed to evaluate these aspects among Saudi adults and to identify associated sociodemographic and health-related factors. Methods: An exploratory, cross-sectional online survey was conducted between August and October 2025 using convenience and snowball sampling. A total of 391 eligible adults (≥18 years, non-healthcare providers) completed an anonymous questionnaire adapted from previously published instruments. Multivariable logistic and ordered logistic regression analyses were performed to examine factors associated with PGx familiarity, attitudes, concerns, willingness to undergo testing, and consent preferences. Results: Attitudes toward PGx testing were strongly positive. Between 70 and 72% of respondents expressed comfort with PGx testing to predict medication efficacy, appropriate dosing, or side effects, and 68% were comfortable when it was recommended by a healthcare provider. The most prominent concerns were privacy breaches (34% high concern) and testing cost (44% high concern). While 71% expressed concern about paying out of pocket for the test, 83% indicated greater willingness if it were free or covered by insurance. Most participants (93%) expected prior notification by their provider, and 85% favored obtaining specific consent for PGx testing. In adjusted models, good/excellent self-rated health was associated with lower odds for high privacy concern (aOR 0.26, 95% CI 0.11-0.64; Conclusion: Acceptance of and interest in PGx testing were high in this online volunteer sample, with privacy and cost as the main barriers. Robust privacy protective measures and integration into healthcare coverage could accelerate the adoption of precision medicine in Saudi Arabia. Findings should be interpreted with caution, given the convenience sampling design and limited generalizability to the broader population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.